Objectives-To determine the effectiveness of intramuscular (IM) ceftriaxone sodium in the treatment of chronic donovanosis, and the acceptability to patients and staff of supervised outpatient treatment in rural clinics. Methods-We collected demographic and sexual health data from participants using a standard questionnaire, and recorded their donovanosis lesions at baseline using genital diagrams. Treatment consisted of a single daily IM injection of 1 g ceftriaxone diluted in 2 ml of 1% lignocaine. Clinic staff followed patients for between three and 12 months, enabling the detection of late recurrences.
Introduction Donovanosis (granuloma inguinale) is a granulomatous genital infection caused by the intracellular gram negative bacillus Calymmatobacterium granulomatis. It is endemic in Aboriginal people in central Australia who often delay contact with health services until their lesions become painful and malodorous, or they experience loss of sexual function due to destruction of genital tissues, scarring and deformity.' Donovanosis often presents a treatment challenge. Empirical treatment with broad spectrum antibiotics has met with variable success,2-'2 and in vitro antibiotic sensitivity testing is unavailable."3 The risk of serious side effects and impractical dosage schedules proscribes the use of some agents.4 5 The advanced lesions frequently seen in central Australia respond poorly to conventional treatment regimens. The antibiotics selected as first line standard treatment in the region, doxycycline and erythromycin, are a compromise between proven efficacy in donovanosis and safety when self-administered. ' 4 Compliance with treatment is also problematic. The need for prolonged antibiotic administration is an important cause of treatment failure in chronic donovanosis, which, in our experience, has led to patient and community dissatisfaction with existing treatment protocols. Hospital admission for supervised treatment has resulted in cures, but is socially disruptive and costly, and many patients discharge themselves before healing is complete.
Ceftriaxone sodium ("Rocephin", Roche Products Pty Ltd) has proven efficacy in the treatment of gonorrhoea, '5 16 syphilis'5 17 18 and chancroid,'5 and is safe in pregnancy'6 and breast feeding. '9 In 1990, we successfully treated two Aboriginal adults with long-standing donovanosis with intramuscular ceftriaxone at a dose of 2 g daily for 10 consecutive days. All lesions healed without relapse. Treatment was well tolerated, with pain at the injection site the only reported side effect. Both patients completed the course of injections without defaulting. Significant improvement was evident within seven days of treatment, and healing continued after cessation of ceftriaxone leaving depigmented scar tissue. Both patients had previously received multiple courses of doxycycline over several years but admitted to poor compliance. The more severely affected patient had also received a supervised course of chloramphenicol; on examination there was complete erosion of the glans penis and disabling scrotal lymphoedema. 1000 Aboriginal people per year. Donovanosis is a notiflable disease in the Northern Territory, and our surveillance data suggest that the incidence of disease varies considerably between communities. We do not know whether these data reflect true differences in incidence or regional differences in the utilisation of health services and reporting practices of medical officers. An informal survey in the catchment communities of one central Australian rural health clinic detected a minimum prevalence of 11 *7 per 1 000 (17/1456), indicating that failure to present for examination and under-reporting by health professionals has led to significant underestimation of the true prevalence.
The successful treatment of donovanosis is dependent on patient compliance, and the commitment of health care providers to encourage defaulting patients and monitor progress over time. In central Australia, poor compliance with self-administrated oral antibiotics has resulted in a cycle of low cure rates, relapse, chronic disease, the need for long and impractical treatment regimens, and delays in presentation for treatment among new and relapsing cases based on the belief that treatment is futile. Anecdotal evidence from health care providers in the region suggests that multiply resistant organisms may be important in compliant patients with relapsing disease. Poor compliance may also be influenced by patients' perception that parenteral antibiotics are more efficacious than oral preparations.29 Given the limitations of standard treatment in our patients, the aims of this study were to determine the efficacy of a parenteral agent in chronic donovanosis, and the feasibility of supervised treatment within a remote area health service infrastructure.
Compliance with the ceftriaxone regimen was very high, especially once clinical improvement was visible to patients. Pain at the injection site was minimised by the use of a small volume of lignocaine for resuspension (2 ml rather than the recommended 3. In spite of the favourable observations of this case series, our study has several limitations. First, we are unable to determine how many inadequately documented patients were started on ceftriaxone, so we may be over-estimating the effect of this agent. This is a recurring difficulty in the provision of medical care to highly mobile populations with health and life style priorities outside the Western medical model. Second, the intrinsic efficacy of ceftriaxone in donovanosis is confounded by the effect of supervised treatment with follow-up under study conditions. Several studies have shown higher cure rates with co-trimoxazole'0 "1 and norfloxacin,1" which are convenient alternatives to parenteral administration. However, these series are not directly comparable with our study population in terms of disease chronicity and observation period. Ramanan and co-workers, for example, successfully treated 10 patients with norfloxacin, but the average duration of disease was 19 days and follow-up was only for one month." The average duration of infection in our patients was three years, suggesting significant local dissemination of the pathogen and general tissue necrosis. We were also able to monitor clinical progress for at least three months in all but one patient, so our ability to detect late relapses may have lowered the apparent cure rate.
Ceftriaxone sodium is not a "magic bullet", but is currently a useful alternative to 
